IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, February 2026
Impact Factor: 8.2

A Review on Artificial Intelligence in Drug Discovery and Molecular Design

Mrs. Nandini Navektan Gaikwad[1], Dr. Ramesh Padu Mhatre[2]
[1]Department of Information Technology
[2]Department of Rural Development
Mahatma Phule Arts, Science and Commerce College, Panvel, Raigad, Maharashtra, India.

Abstract: *Artificial Intelligence (AI) is increasingly reshaping pharmaceutical research by enhancing efficiency, lowering development costs, and shortening drug discovery timelines. Conventional drug discovery methods are highly resource-intensive, often taking more than a decade and requiring substantial financial investment, with a high probability of failure during clinical testing phases. AI-driven technologies such as Machine Learning (ML), Deep Learning (DL), Generative AI, and Graph Neural Networks (GNNs) provide data-driven solutions that improve the identification, screening, and optimization of drug candidates. These technologies can analyze complex biological and chemical datasets, predict molecular interactions, design novel compounds, and assess drug safety profiles with higher accuracy and speed.*

Recent advancements highlight the growing role of AI in protein structure prediction, molecular property estimation, toxicity prediction, drug repurposing, and clinical trial optimization. AI also supports personalized medicine by enabling precise treatment strategies based on genetic and molecular data. This review paper presents a comprehensive overview of major AI techniques used in drug discovery and molecular design. It further discusses real-world applications across different stages of the drug discovery pipeline, industrial impact, existing technical and ethical challenges, and emerging research opportunities. The study emphasizes the importance of integrating AI with traditional pharmaceutical research to accelerate innovation and improve global healthcare outcomes.

Keywords*:* Artificial Intelligence, Drug Discovery, Molecular Design, Machine Learning, Deep Learning, Generative AI, Computational Drug Design

I. INTRODUCTION

Drug discovery has traditionally been a long, complex, and expensive process, often requiring 10–15 years and billions of dollars to successfully develop and commercialize a new drug.[4] The pharmaceutical industry continues to face major challenges, including high failure rates during clinical trials, the complexity of biological systems, difficulties in identifying suitable drug targets, and the increasing cost of research and development. Conventional drug discovery approaches rely heavily on trial-and-error experimentation, which slows down innovation and increases financial risk. In recent years, Artificial Intelligence (AI) has emerged as a transformative technology capable of addressing these limitations.[1],[5] AI enables predictive modeling, automated molecular design, and intelligent data analysis, allowing researchers to process massive biological and chemical datasets efficiently. By using advanced algorithms, AI can identify potential drug targets, predict molecular behavior, and optimize drug candidates much faster than traditional computational and laboratory methods.[2]

Despite significant advancements in AI-based drug discovery, several challenges remain. Traditional drug discovery methods are still widely used due to regulatory requirements, lack of standardized data infrastructure, and concerns about AI model reliability. Although AI has demonstrated strong performance in research environments, its full integration into real-world pharmaceutical workflows remains limited.[6] Key barriers include poor data quality, limited access to high-quality biological datasets, regulatory uncertainties, and difficulties in interpreting complex AI

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, February 2026
Impact Factor: 8.2

models. Therefore, there is a need for further research to develop reliable, transparent, and regulatory-compliant AI systems that can be effectively integrated into pharmaceutical research and development processes.

II. OBJECTIVES

• Analyze AI techniques used in drug discovery:

This objective focuses on understanding how different AI technologies such as Machine Learning, Deep Learning, Generative AI, and Graph Neural Networks are applied in drug discovery. It includes studying how these techniques help in target identification, drug screening, toxicity prediction, and molecular property prediction. The aim is to evaluate how AI improves speed, accuracy, and efficiency compared to traditional drug discovery methods.

• Study applications in molecular design:

This point examines how AI supports the design and development of new drug molecules. AI models can generate novel molecular structures, optimize chemical properties, and predict biological activity. This helps researchers design safer and more effective drug candidates with reduced experimental cost and time.

• Evaluate benefits and limitations:

This objective analyzes the advantages of AI, such as faster drug development, cost reduction, improved prediction accuracy, and automation. It also studies limitations including data quality issues, model interpretability challenges, regulatory barriers, and dependency on large datasets.

• Identify future research directions:

This focuses on exploring upcoming opportunities such as explainable AI, integration with quantum computing, personalized medicine, and improved regulatory frameworks. It helps in understanding how AI can be further improved for real-world pharmaceutical applications.

III. LITERATURE REVIEW

Recent research shows that Artificial Intelligence is playing an important role in making drug discovery faster and more reliable. Earlier, scientists had to spend years studying proteins, molecular reactions, and drug toxicity through laboratory experiments. Now, AI models can study large biological datasets and predict protein structures, molecular interactions, and possible toxicity risks with high accuracy. This helps researchers make better decisions in the early stages and reduces the chances of failure during later clinical trials.[2],[7]

At the same time, Generative AI has become a powerful tool in modern drug research. These models can design completely new molecules and even help in protein structure generation. Instead of testing thousands of chemicals manually, AI can explore huge chemical possibilities digitally and suggest promising drug candidates. This not only saves time but also opens doors to discovering innovative medicines that may not have been found using traditional methods.[8]

Moreover, recent AI systems can design molecules that are not only effective but also possible to manufacture in real laboratory conditions. They can predict drug feasibility early, helping pharmaceutical companies reduce testing costs and speed up development. Overall, current studies show that AI is making drug discovery more efficient, smarter, and more cost-effective.[9]

IV. METHODOLOGY

This study uses a systematic review methodology to understand how Artificial Intelligence is being applied in drug discovery and molecular design. Instead of conducting laboratory experiments, this research analyzes already published high-quality scientific studies. The data for this review was collected from trusted academic databases such as Scopus-indexed journals, IEEE Xplore, ScienceDirect, and PubMed. These sources are widely recognized for publishing reliable and peer-reviewed research in pharmaceutical and technology fields.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, February 2026
Impact Factor: 8.2

To ensure the relevance and quality of the review, only research papers published between 2023 and 2026 were selected. The study focused mainly on peer-reviewed journal articles that specifically discuss AI applications in drug discovery and molecular design. This helps maintain the accuracy and credibility of the research findings.

The review framework followed a structured process. First, relevant research papers were collected from selected databases. Next, screening was performed to remove duplicate or unrelated studies. After that, thematic analysis was conducted to identify major research themes, AI techniques, and application areas. Finally, comparative evaluation was performed to compare different AI methods based on performance, applications, and limitations. This systematic approach ensures a clear and unbiased understanding of current research trends in AI-based drug discovery.[10]

V. AI TECHNIQUES IN DRUG DISCOVERY

5.1 Machine Learning

Machine Learning plays a major role in modern drug discovery by helping researchers analyze complex biological and chemical data quickly. ML algorithms are widely used for predicting drug-target interactions, which helps scientists understand how a drug will interact with a specific protein or disease target. It is also used in toxicity prediction to identify harmful side effects at an early stage. Another important application is drug repurposing, where ML helps identify new uses for existing drugs. By learning patterns from large datasets, ML models improve prediction accuracy and reduce experimental time and cost.[1],[5]

5.2 Deep Learning

Deep Learning is an advanced form of machine learning that uses neural networks to process complex data. It has significantly improved protein structure prediction, helping scientists understand disease mechanisms more clearly. Deep learning is also used for molecular property prediction, such as solubility and stability of drug compounds. Additionally, it supports biomedical image analysis, such as analyzing cell images or medical scans. Deep neural networks have greatly improved biological data interpretation and molecular interaction modeling.[2],[7]

5.3 Generative AI

Generative AI is used to create new drug molecules instead of only analyzing existing ones. It supports de novo drug design, molecular optimization, and chemical structure generation. These models can explore large chemical spaces and suggest new potential drug candidates, making drug discovery faster and more innovative.[8],[9]

5.4 Graph Neural Networks (GNNs)

Graph Neural Networks are designed to study molecular structures by representing molecules as graph networks. GNNs help predict molecular properties, analyze protein interactions, and improve molecular similarity modeling, which is important for identifying effective drug compounds.[11]

VI. APPLICATIONS IN DRUG DISCOVERY PIPELINE

Artificial Intelligence is now being used across multiple stages of the drug discovery pipeline, making the overall process faster, smarter, and more efficient. In the target identification stage, AI analyzes biological data such as genomic and proteomic information to identify disease-causing proteins or genes that can be targeted by drugs. This helps researchers focus on the most promising biological targets early in the research process.[5]

During virtual screening, AI models quickly analyze millions of chemical compounds and predict which molecules are most likely to bind effectively with the disease target. This reduces the need for large-scale laboratory testing and saves both time and cost.[1],[2]

In the lead optimization stage, AI helps improve selected drug candidates by predicting properties such as toxicity, solubility, stability, and effectiveness. This ensures that only the most promising molecules move forward in the development process.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, February 2026
Impact Factor: 8.2

AI is also useful in clinical trial analysis, where it helps in patient selection, predicting drug response, and monitoring safety outcomes. This improves trial success rates and reduces overall development time.[3]



Figure 1: Drug Discovery Architecture

The architecture shows how the drug discovery process flows using AI. First, biological data is collected from various sources. This data is then processed using AI models. These models perform molecular prediction to identify how molecules behave biologically. Finally, the best potential drug candidates are selected for further testing and development.

VII. MOLECULAR DESIGN USING AI

Artificial Intelligence has fundamentally changed how new drug molecules are designed. Traditionally, molecular design relied heavily on trial-and-error laboratory experiments, which were slow and expensive. AI now enables data-driven molecular innovation, allowing researchers to generate, evaluate, and optimize drug candidates computationally before synthesis.

AI supports three major capabilities:

Novel molecule generation: Generative models (such as VAEs, GANs, and diffusion models) can create entirely new chemical structures that do not exist in current databases. This helps researchers explore vast chemical space efficiently.[8]

Property optimization: AI models predict key drug properties like solubility, bioavailability, binding affinity, and toxicity. Based on these predictions, molecules can be iteratively refined to improve effectiveness and safety.[2]

Drug repurposing: AI analyzes existing approved drugs and identifies new therapeutic uses, significantly reducing development time and cost.[5]

This pipeline represents the core computational workflow:



Figure 2: AI Drug Discovery Pipeline

1. Data Collection

Large-scale biological, chemical, and clinical datasets are gathered from databases such as genomics, proteomics, and chemical libraries. High-quality data is critical because AI models learn patterns from these inputs.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, February 2026
Impact Factor: 8.2

2. Feature Extraction
Raw data is converted into machine-readable numerical representations (molecular descriptors, fingerprints, embeddings). This step improves model learning efficiency.

3. AI Training
Machine learning or deep learning models are trained using prepared datasets. During training, the model learns relationships between molecular structures and biological activity.

4. Molecule Generation
Generative AI or predictive models propose new drug candidates or optimized molecular structures with desired properties.

5. Validation
Generated molecules undergo computational validation (ADMET prediction, docking) and later experimental validation to ensure safety and effectiveness.

Flowchart: AI Drug Discovery Process:



This flowchart represents the end-to-end pharmaceutical pipeline enhanced by AI:
Start: Research begins with a disease problem.
Data Collection: Biological and chemical data are gathered.
Target Identification: AI helps identify disease-related proteins or genes.
AI Model Training: Models learn from historical drug–target data.
Molecule Generation: AI designs or screens potential drug compounds.
Validation: Promising molecules undergo computational and lab testing.
Clinical Trials: Selected candidates are tested on humans in phases.
Drug Approval: Regulatory approval is granted for successful drugs.
This AI-driven workflow significantly reduces time, cost, and failure risk compared to traditional drug discovery. Below table shows the **AI Techniques Comparison**

AI Techniques	Strengths	Limitations
Machine Learning	Fast prediction	Needs quality data
Deep Learning	High accuracy	High computation cost
Generative AI	New molecule creation	Validation needed
GNN	Molecular representation	Complex training

Benefits and Industrial Impact

Faster Drug Discovery: AI automates large-scale data analysis and virtual screening, significantly shortening the time required to identify promising drug candidates.

Cost Reduction: By minimizing laboratory experiments and early-stage failures, AI helps pharmaceutical companies reduce overall research and development expenses.

Improved Clinical Success Rates: Predictive models enable better candidate selection, lowering the risk of late-stage clinical trial failures.

Enhanced Decision-Making: AI-driven insights support researchers in making more accurate and data-informed decisions throughout the drug development process.

Support for Personalized Medicine: AI analyzes genomic and patient-specific data to enable customized treatment strategies tailored to individual patient needs.

Increased Industrial Productivity: Automation of routine research tasks improves operational efficiency within pharmaceutical organizations.

Competitive Advantage: Companies adopting AI technologies gain faster innovation cycles and stronger positioning in the global pharmaceutical market.[1],[3]

Challenges and Limitations :

Despite its promise, AI-driven drug discovery faces several practical barriers. One major issue is data quality and availability, as many biological datasets are incomplete, biased, or poorly standardized. Regulatory pathways for AI-designed drugs are still evolving, creating approval uncertainties for industry adoption. Ethical concerns related to data privacy and algorithmic bias also require careful governance. Additionally, many advanced AI models function as black boxes, making their predictions difficult to interpret and trust in high-stakes pharmaceutical decision-making. Addressing these limitations is essential for wider real-world deployment.[6],[12]

Future Research Directions :

Future research in AI-driven drug discovery is expected to concentrate on building systems that are not only powerful but also transparent, trustworthy, and easily deployable in real pharmaceutical environments. One of the most important areas is Explainable Artificial Intelligence (XAI). Many current AI models operate as black boxes, making it difficult for scientists and regulators to understand how predictions are made. Future work will focus on developing interpretable models that provide clear reasoning behind drug predictions, which will improve user trust and support regulatory approval processes.[12]

Another key direction is the integration of multi-modal biomedical data. Drug discovery increasingly depends on combining diverse data sources such as genomics, proteomics, metabolomics, electronic health records, and medical imaging. Future AI systems will be designed to fuse these heterogeneous datasets into unified predictive frameworks, enabling a more comprehensive understanding of disease mechanisms and drug responses.[5]

Emerging technologies such as quantum AI for molecular simulation are also gaining attention. Quantum computing has the potential to simulate complex molecular interactions far more accurately than classical computers, which could dramatically improve drug design precision. Additionally, researchers are working toward fully autonomous drug discovery laboratories, where robotics, AI, and high-throughput experimentation operate in closed-loop systems with minimal human intervention.[13]

Finally, stronger collaboration among AI researchers, pharmaceutical companies, healthcare institutions, and regulatory bodies will be essential. Standardized data-sharing protocols, ethical AI governance, and clear regulatory guidelines will play a critical role in translating AI innovations from research labs into real-world clinical and industrial applications.

ISSN: 2581-9429 Volume 6, Issue 4, February 2026 Impact Factor: 8.2

VI. CONCLUSION

Artificial Intelligence is rapidly transforming pharmaceutical research and molecular design by making drug discovery faster, more accurate, and more cost-effective than traditional approaches. Technologies such as machine learning, deep learning, generative AI, and graph neural networks are enabling researchers to analyze complex biological data, predict molecular behavior, and design novel drug candidates with greater precision. As a result, AI is improving efficiency across the entire drug development pipeline—from target identification and virtual screening to lead optimization and clinical trial support.

The integration of AI into pharmaceutical workflows has already demonstrated significant potential in reducing development timelines, lowering research costs, and improving clinical success rates. However, important challenges still need to be addressed. Issues related to data quality, limited availability of standardized datasets, model interpretability, ethical concerns, and evolving regulatory frameworks continue to slow full-scale industrial adoption. Overcoming these barriers will require advances in explainable AI, stronger data governance, and closer collaboration between technology developers, pharmaceutical companies, and regulatory authorities.

Looking ahead, AI is expected to become a central pillar of pharmaceutical innovation. With continued progress in multi-modal data integration, autonomous research systems, and high-performance computing, AI-driven drug discovery will likely enable the development of safer, more effective, and highly personalized therapies. Ultimately, the successful convergence of AI and pharmaceutical science has the potential to significantly improve global healthcare outcomes and accelerate the delivery of next-generation medicines.

REFERENCES

[1] S. Vamathevan et al., "Applications of machine learning in drug discovery and development," Nature Reviews Drug Discovery, vol. 23, no. 1, pp. 1–22, 2024.

[2] J. Jumper et al., "Highly accurate protein structure prediction with AlphaFold," Nature, vol. 596, pp. 583–589, 2021.

[3] K. H. Mak and M. R. Pichika, "Artificial intelligence in drug development: present status and future prospects," Drug Discovery Today, vol. 28, no. 3, 2023.

[4] P. Pushpakom et al., "Drug repurposing: progress, challenges and recommendations," Nature Reviews Drug Discovery, vol. 18, no. 1, pp. 41–58, 2019.

[5] A. Zhavoronkov et al., "Deep learning enables rapid identification of potent DDR1 kinase inhibitors," Nature Biotechnology, vol. 37, pp. 1038–1040, 2019.

[6] European Medicines Agency, "Reflection paper on the use of artificial intelligence in the medicinal product lifecycle," EMA, 2023.

[7] M. Baek et al., "Accurate prediction of protein structures and interactions using a three-track neural network," Science, vol. 373, no. 6557, 2021.

[8] R. Gómez-Bombarelli et al., "Automatic chemical design using a data-driven continuous representation of molecules," ACS Central Science, vol. 4, no. 2, pp. 268–276, 2018.

[9] J. M. Stokes et al., "A deep learning approach to antibiotic discovery," Cell, vol. 180, no. 4, pp. 688–702, 2020.

[10] B. Kitchenham, "Procedures for performing systematic reviews," Keele University Technical Report, 2004.

[11] Z. Wu et al., "A comprehensive survey on graph neural networks," IEEE Transactions on Neural Networks and Learning Systems, vol. 32, no. 1, pp. 4–24, 2021.

[12] A. Holzinger et al., "What do we need to build explainable AI systems for the medical domain?" arXiv:1712.09923, updated 2023.

[13] J. Cao et al., "Quantum chemistry in the age of quantum computing," Chemical Reviews, vol. 119, no. 19, pp. 10856–10915, 2019.

DOI: 10.48175/IJARSCT-31721